Humoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults ≥60 Years.
BNT162b2
COVID-19
SARS-CoV-2
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
08 May 2022
08 May 2022
Historique:
received:
24
03
2022
revised:
03
05
2022
accepted:
04
05
2022
entrez:
14
5
2022
pubmed:
15
5
2022
medline:
15
5
2022
Statut:
epublish
Résumé
Both humoral and cellular anamnestic responses are significant for protective immunity against SARS-CoV-2. In the current study, the responses in elderly people before and after a fourth vaccine dose of BNT162b2 were compared to those of individuals immunized with three vaccine doses. Although a boost effect was observed, the high response following the third administration questions the necessity of an early fourth boost.
Identifiants
pubmed: 35566774
pii: jcm11092649
doi: 10.3390/jcm11092649
pmc: PMC9101339
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Science. 2021 Dec 03;374(6572):abm0829
pubmed: 34648302
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
Lancet. 2021 Dec 4;398(10316):2093-2100
pubmed: 34756184
Viruses. 2022 Feb 08;14(2):
pubmed: 35215940
Cell. 2022 Mar 3;185(5):847-859.e11
pubmed: 35139340
N Engl J Med. 2022 Apr 7;386(14):1377-1380
pubmed: 35297591
Nat Med. 2021 Nov;27(11):1874-1875
pubmed: 34764485
N Engl J Med. 2022 May 5;386(18):1712-1720
pubmed: 35381126
JAMA. 2021 Dec 7;326(21):2203-2204
pubmed: 34739043